肠道微生物群与免疫疗法
Gut Microbiota and Immunotherapy.
作者信息
Xu Xiaoqing, Ying Jieer
机构信息
Department of Medical Oncology, The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
Department of Hepato-Pancreato-Biliary and Gastric Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
出版信息
Front Microbiol. 2022 Jul 1;13:945887. doi: 10.3389/fmicb.2022.945887. eCollection 2022.
The gut microbiota is the largest microbiota in the body, which is closely related to the immune state of the body. A number of studies have shown that gut microbiota and its metabolites are involved in host immune regulation. Immune checkpoint inhibitors have become an important drug for the treatment of many malignant tumors, which can significantly improve the prognosis of tumor patients. However, a considerable number of patients cannot benefit from immune checkpoint inhibitors. At present, the known treatment methods of microbiota manipulation mainly include fecal microbiota transplantation, dietary regulation, prebiotics and so on. Therefore, this paper will discuss the possibility of improving the anti-tumor efficacy of immunotherapy from the perspectives of the gut microbiota and immunotherapy.
肠道微生物群是体内最大的微生物群，与机体的免疫状态密切相关。多项研究表明，肠道微生物群及其代谢产物参与宿主免疫调节。免疫检查点抑制剂已成为治疗多种恶性肿瘤的重要药物，可显著改善肿瘤患者的预后。然而，相当一部分患者无法从免疫检查点抑制剂中获益。目前，已知的微生物群调控治疗方法主要包括粪便微生物群移植、饮食调节、益生元等。因此，本文将从肠道微生物群和免疫治疗的角度探讨提高免疫治疗抗肿瘤疗效的可能性。
Zotero 插件